Exploitation of Microalgae Species for Nutraceutical Purposes: Cultivation Aspects

Saha, Sukant; Murray, Patrick G.

doi:10.3390/fermentation4020046

Cited by 48 publications

(25 citation statements)

References 80 publications

(83 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The use of microalgae as human food is not unusual as it can be traced back many years in indigenous populations from China, Japan, and the Republic of Korea [7]. The traditional knowledge of microalgae use by these indigenous people has now disseminated throughout the world population through migration.…”

Section: Introductionmentioning

confidence: 99%

Marine Microalgae for Potential Lutein Production

2020

Self Cite

View full text Add to dashboard Cite

Lutein is particularly known to help maintain normal visual function by absorbing and attenuating the blue light that strikes the retina in our eyes. The effect of overexposure to blue light on our eyes due to the excessive use of electronic devices is becoming an issue of modern society due to insufficient dietary lutein consumption through our normal diet. There has, therefore, been an increasing demand for lutein-containing dietary supplements and also in the food industry for lutein supplementation in bakery products, infant formulas, dairy products, carbonated drinks, energy drinks, and juice concentrates. Although synthetic carotenoid dominates the market, there is a need for environmentally sustainable carotenoids including lutein production pathways to match increasing consumer demand for natural alternatives. Currently, marigold flowers are the predominant natural source of lutein. Microalgae can be a competitive sustainable alternative, which have higher growth rates and do not require arable land and/or a growth season. Currently, there is no commercial production of lutein from microalgae, even though astaxanthin and β-carotene are commercially produced from specific microalgal strains. This review discusses the potential microalgae strains for commercial lutein production, appropriate cultivation strategies, and the challenges associated with realising a commercial market share.

show abstract

Section: Introductionmentioning

confidence: 99%

Marine Microalgae for Potential Lutein Production

2020

Self Cite

View full text Add to dashboard Cite

show abstract

“…Chlorella vulgaris grown under nitrogen-rich conditions achieved a maximum lipid productivity of 71.1 mg L −1 d −1 [ 200 ]. Chlorococcum , a cosmopolitan microalga tolerant to extreme pH and temperature, produces astaxanthin, canthaxanthin, lutein, β-carotene, adonixanthin, and cis-isomers of ketocarotenoid [ 201 ]. H. Plulvalis accumulates 95% of total carotenoids and increased fatty acid biosynthesis due to improvements in environmental conditions (light strength, temperature, salinity, and nutrient limitation) [ 202 ].…”

Section: Microalgae Cultivationmentioning

confidence: 99%

Microalgal Cell Biofactory—Therapeutic, Nutraceutical and Functional Food Applications

Kiran

Mohan

2021

Plants

View full text Add to dashboard Cite

Microalgae are multifaceted photosynthetic microorganisms with emerging business potential. They are present ubiquitously in terrestrial and aquatic environments with rich species diversity and are capable of producing significant biomass. Traditionally, microalgal biomass is being used as food and feed in many countries around the globe. The production of microalgal-based bioactive compounds at an industrial scale through biotechnological interventions is gaining interest more recently. The present review provides a detailed overview of the key algal metabolites, which plays a crucial role in nutraceutical, functional foods, and animal/aquaculture feed industries. Bioactive compounds of microalgae known to exhibit antioxidant, antimicrobial, antitumor, and immunomodulatory effects were comprehensively reviewed. The potential microalgal species and biological extracts against human pathogens were also discussed. Further, current technologies involved in upstream and downstream bioprocessing including cultivation, harvesting, and cell disruption were documented. Establishing microalgae as an alternative supplement would complement the sustainable and environmental requirements in the framework of human health and well-being.

show abstract

“…EPA and DHA intake can come from a diet high in fish or through dietary supplementation with fish oils or purified oils [34]. Other, more sustainable sources of EPA and DHA include algae [35,36], which can also be exploited for their rich abundance of other bioactive compounds such as angiotensin converting enzyme inhibitor peptides and antiviral agents including phycobiliproteins, sulfated polysaccharides, and calcium-spirulan [37]. n-3 PUFAs have been investigated for many years for their therapeutic potential [38].…”

Section: N-3 Pufamentioning

confidence: 99%

High-dose vitamin C infusion for the treatment of critically ill COVID-19

Rao

Zhu

et al. 2020

Preprint

View full text Add to dashboard Cite

BackgroundNo specific medication has been proven effective for the treatment of patients with severe coronavirus disease 2019 (COVID-19). Here, we tested whether high-dose vitamin C infusion was effective for severe COVID-19.MethodsThis randomized, controlled clinical trial was performed at 3 hospitals in Hubei, China. Patients with confirmed severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in the ICU were randomly assigned in as 1:1 ratio to either the high-dose intravenous vitamin C (HDIVC) or the placebo. HDIVC group received 12 g of vitamin C/50 ml every 12 hours for 7 days at a rate of 12 ml/hour, and the placebo group received bacteriostatic water for injection in the same way. The primary outcome was invasive mechanical ventilation-free days in 28 days(IMVFD28). Secondary outcomes were 28-day mortality, organ failure, and inflammation progression.ResultsFifty-four critical COVID-19 patients were ultimately recruited. There was no difference in IMVFD28 between two groups. During the 7-day treatment period, patients in the HDIVC group had a steady rise in the PaO2/FiO2 (day 7: 229 vs. 151 mmHg, 95% CI 33 to 122, P = 0.01). Patients with SOFA scores ≥ 3 in the HDIVC group exhibited a significant reduction in 28-day mortality (P = 0.05) in univariate survival analysis. IL-6 in the VC group was lower than that in the placebo group (19.42 vs. 158.00; 95% CI -301.72 to -29.79; P = 0.04) on day 7.ConclusionThe addition of HDIVC may provide a protective clinical effect without any adverse events in critically ill patients with COVID-19.Clinicaltrial.gov identifer: NCT04264533

show abstract

Exploitation of Microalgae Species for Nutraceutical Purposes: Cultivation Aspects

Cited by 48 publications

References 80 publications

Marine Microalgae for Potential Lutein Production

Marine Microalgae for Potential Lutein Production

Microalgal Cell Biofactory—Therapeutic, Nutraceutical and Functional Food Applications

High-dose vitamin C infusion for the treatment of critically ill COVID-19

Contact Info

Product

Resources

About